Logo

Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar- ranibizumab) in the US and Canada

Share this
Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar- ranibizumab) in the US and Canada

Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar- ranibizumab) in the US and Canada

Shots:

  • STADA and Xbrane to receive up front and milestones upon approval and launch of the Xlucane in the US and will be eligible to get an equal share of profits from sales of the biosimilar. The companies aim to obtain all currently approved indications for Lucentis in the US and Canada
  • Xbrane and STADA will finalize the development of the Xlucane with Xbrane providing the commercial supply. Following regulatory approval- Bausch + Lomb will be responsible for marketing and commercialization of the biosimilar in the US and Canada
  • The addition of biosimilar candidate to Lucentis (ranibizumab) to Bausch + Lomb’s portfolio will expand its ophthalmic portfolio. Under the collaboration- STADA and Xbrane will leverage Bausch + Lomb’s expertise in the North American ophthalmic market

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bausch + Lomb


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions